Vision Restoration via Mutation-Agnostic Optogenetic Therapy: ZM-02 Opportunity
Time: 1:45 pm
day: Conference Day One
Details:
- Introducing ZM-02 optogenetic therapy enabling light-sensitive protein expression to restore vision to patients with severe retinal degeneration
- Delivering a mutation-agnostic approach allowing treatment across genetic profiles to broaden access for diverse patient populations
- Showcasing first-in-human clinical data demonstrating safety and functional vision improvement to validate ZM-02’s therapeutic potential
